Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
|
19483472 |
2009 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
|
31335987 |
2020 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Another variant (rs701848) in the 3'UTR region of PTEN was associated with increased RCC risk (P = 0.014, OR = 1.45, 95%CI = 1.08-1.96, CC vs. TT); however, the association was not significant after adjusting for multiple comparisons.
|
23209702 |
2012 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Because loss of PTEN can activate mTOR and mTOR inhibitors are Food and Drug Administration approved to treat renal cell carcinoma, these agents have clinical potential in renal cell carcinoma associated with Cowden syndrome.
|
23764071 |
2013 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.
|
27779645 |
2016 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of PTEN-Long in serum of patients with nephritis, renal cell carcinoma (RCC) as well as normal controls, and in serum and renal tissues of mice were measured by western blotting.
|
30680021 |
2019 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Expression of PTEN in 40 cases of renal cell carcinoma were different, 12.5% were negative, 17.5% were weak positive, and 70% were strong positive.
|
12452054 |
2002 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, 19 of 20 advanced RCC showed somatic hypermethylation upstream of KILLIN, with the majority hypermethylated at more than one CpG island (13/19 vs. 3/23 with germline methylation, P < 0.0001). qRT-PCR revealed that methylation significantly downregulates KILLIN expression (P = 0.05), and demethylation treatment by 5-aza-2'deoxycytidine significantly increased KILLIN expression in all RCC cell lines while only increasing PTEN expression in one line.
|
21584899 |
2011 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
RGD |
Here, we have investigated the activity of PI 3-K and the expression of PTEN, p53, tuberin, p-mTOR, and p-p70S6K in both Eker rat RCC and human renal AML.
|
22737271 |
2011 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
However, the low frequency of biallelic inactivation suggests that either PTEN/MMAC1 is inactivated by other mechanisms or it is not the only target of chromosome 10q deletion in primary bladder and renal cell cancer.
|
9671402 |
1998 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study suggested that the miR-22/PTEN axis may be considered a novel therapeutic target in RCC.
|
27082730 |
2016 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In summary, we conclude that DLX6-AS1 promotes renal cell carcinoma development via regulation of miR-26a/PTEN axis.
|
28881158 |
2017 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Inactivated GSK3β, decreased PTEN expression and PAX2 positivity were observed in the vast majority of the multilocular cystic renal cell carcinomas.
|
21151099 |
2011 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
miR‑205 suppresses cell proliferation, invasion, and metastasis via regulation of the PTEN/AKT pathway in renal cell carcinoma.
|
27498834 |
2016 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Other genes involved in regulating hypoxia-inducible factor [e.g. genes encoding carbonic anhydrase-IX and PTEN (phosphatase and tensin homolog)] were reported to be prognostically important in renal cell carcinoma.
|
17762621 |
2007 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that PTEN mutation is observed in a subset of RCCs and that, especially in clear-cell RCCs, it occurs as a late-stage event and may contribute to the invasive and/or metastatic tumor phenotype.
|
11146448 |
2001 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PHTS is a hereditary syndrome newly associated with pRCC, and PTEN IHC may be a helpful screening tool to identify pRCC patients with PHTS.
|
22381246 |
2012 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Relationship between PTEN and Livin expression and malignancy of renal cell carcinomas.
|
22938441 |
2012 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma.
|
25714556 |
2015 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Renal tumours (renal cell carcinomas and oncocytomas) express PTEN protein predominantly in the cytoplasm.
|
17886097 |
2007 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma.
|
10628321 |
2000 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
|
25401301 |
2015 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken together, the findings indicated for the first time that miR-193a-3p functions as a tumor-promoting microRNA by directly targeting PTEN in renal cell carcinoma.
|
28639901 |
2017 |